$1,318.00
This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Surgery
9 Chemotherapy
9 Radiation therapy
9 Targeted therapies
11 EPIDEMIOLOGY
11 Epidemiological disease definition
17 MARKETED DRUGS
20 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 Yondelis for Sarcoma (September 20, 2021)
30 ADP-A2M4 for Sarcoma (May 19, 2021)
31 Xpovio for Sarcoma (November 2, 2020)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Aadi Starts Small With Fyarro, But Has Tumor-Agnostic Strategy In Mind
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 Tracon Obtains CTLA-4 Antibody Rights In North America From Eucure
38 REVENUE OPPORTUNITY
39 CLINICAL TRIAL LANDSCAPE
40 Sponsors by status
41 Sponsors by phase
42 Recent events
44 BIBLIOGRAPHY
46 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of sarcoma, 2019–28
15 Figure 2: Incident cases of sarcoma, by age, 2019
16 Figure 3: Incident cases of sarcoma, by tumor type, 2019
20 Figure 4: Overview of pipeline drugs for sarcoma in the US
20 Figure 5: Pipeline drugs for sarcoma, by company
21 Figure 6: Pipeline drugs for sarcoma, by drug type
21 Figure 7: Pipeline drugs for sarcoma, by classification
31 Figure 8: ADP-A2M4 for Sarcoma (May 19, 2021): Phase II – SPEARHEAD-1
33 Figure 9: Xpovio for Sarcoma (November 2, 2020): Phase II/III – SEAL
34 Figure 10: Key upcoming events in sarcoma
36 Figure 11: Probability of success in the sarcoma pipeline
39 Figure 12: Clinical trials in sarcoma
39 Figure 13: Top 10 drugs for clinical trials in sarcoma
40 Figure 14: Top 10 companies for clinical trials in sarcoma
40 Figure 15: Trial locations in sarcoma
41 Figure 16: Sarcoma trials status
42 Figure 17: Sarcoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of sarcoma, 2019–28
18 Table 2: Marketed drugs for sarcoma
22 Table 3: Pipeline drugs for sarcoma in the US
29 Table 4: Yondelis for Sarcoma (September 20, 2021)
30 Table 5: ADP-A2M4 for Sarcoma (May 19, 2021)
32 Table 6: Xpovio for Sarcoma (November 2, 2020)
38 Table 7: Historical global sales, by drug ($m), 2017–21
38 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!